GlassScriptPhysician profile
Kenneth R Kenyon
NPI 1285620948
$23,978.16
in general payments reported to CMS, 2019-2025
12 companies · $34.82 in 2025
The $34.82 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $24.86 · 2021: $7,745 · 2022: $6,923 · 2023: $15.00 · 2024: $8,647 · 2025: $34.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,544 · Travel and Lodging: $92.39 · Food and Beverage: $60.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,544.00 |
| Travel and Lodging | $92.39 |
| Food and Beverage | $60.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $14,700.00 | 2021-2024 | |
| Biotissue Holdings INC. | $7,883.25 | 2019-2024 | |
| Alcon Vision LLC | $950.15 | 2019-2024 | |
| Galderma Laboratories, L.P. | $119.42 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.33 | 2019 | |
| Dompe US, INC. | $85.65 | 2019 | |
| Abbvie INC. | $60.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $49.58 | 2019-2020 | |
| Eyepoint US, INC. | $15.46 | 2019 | |
| Shire North American Group INC | $14.08 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kenyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.